Jul 29, 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Jul 25, 2019
ADVANZ PHARMA Corp. Comments on CMA Statement of Objections Related to Nitrofurantoin
Oct 24, 2018
Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
Sep 28, 2018
Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Aug 23, 2018
FDA approves DIACOMIT (Stiripentol) for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam
May 30, 2018
Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)
Apr 19, 2018
Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA
Mar 30, 2018
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications
Feb 05, 2018
Embrace by Empatica is the world's first smart watch to be cleared by FDA for use in Neurology
Nov 22, 2017
Eisai Announces Presentations on Perampanel (marketed as FYCOMPA CIII) at the Annual Meeting of the American Epilepsy Society (AES)
Nov 06, 2017
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
Sep 15, 2017
New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
Aug 23, 2017
Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome
Jul 26, 2017
FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures